Novo Nordisk CSO Outlines Obesity R&D Strategy, Calls Condition "Ticking Time Bomb"

Mads Krogsgaard Thomsen, Novo Nordisk AS's chief science officer, says that although the medical understanding of and treatments for obesity are woefully inadequate, the advance of promising innovation and growing patient databases will soon ensure that the condition becomes acknowledged as a serious but treatable disease by regulators, payers and politicians.

The Danish scientist also said in an interview that Novo Nordisk was leading the way in developing treatments for obesity armed with a handful of pipeline projects that address both appetite reduction and energy expenditure, led by the firm's ground-breaking GLP-1 semaglutide